Nancy H.C. Loos

Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Irene A. Retmana, Nancy H.C. Loos, Alfred H. Schinkel et al. · Journal of Chromatography B · 2021 · 17 citations · Full text

P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib

Margarida L.F. Martins, Nancy H.C. Loos, Sümeyra Mucuk et al. · Molecular Pharmaceutics · 2021 · 17 citations

ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites

Alejandra Martínez-Chávez, Nancy H.C. Loos, Maria C. Lebre et al. · Pharmacological Research · 2021 · 17 citations

Active Metabolites, Total Plasma Exposure, Medicine +9

ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability

Nancy H.C. Loos, Irene A. Retmana, Wenlong Li et al. · Pharmacological Research · 2022 · 11 citations · Full text

Whereas Abcb1, Medicine, Mechanism Of Action +10

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c

Nancy H.C. Loos, Irene A. Retmana, Jamie Rijmers et al. · Biomedicine & Pharmacotherapy · 2023 · 10 citations · Full text